As of Friday close, Prothena Corporation plc’s (NASDAQ:PRTA) stock was down -$1.24, moving down -2.14 percent to $56.75. The average number of shares traded per day over the past five days has been 445,260 shares. 1 time new highs have been achieved over the past 5 days, with a -$5.36 fall in that time frame. In the last twenty days, the average volume was 406,860, while in the previous 50 days, it was 395,426.
Since last month, PRTA stock retreated -14.31%. Shares of the company fell to $55.69 on 08/18/23, the lowest level in the past month. A 52-week high of $79.65 was reached on 05/05/23 after having rallying from a 52-week low of $25.02. Since the beginning of this year, PRTA’s stock price has dropped by -5.81% or -$3.50, and marked a new high 4 times. However, the stock has declined by -28.75% since its 52-week high.
PRTA stock investors should be aware that Prothena Corporation plc (PRTA) stock had its last reported insider trading activity 1 day ago on Aug 18. Walker Karin L, the Chief Accounting Officer of the company, disposed of 5,000 shares for $57.18 on Aug 18. It resulted in a $285,922 divestment by the insider. Smith Brandon S. sold 4,000 shares at an average price of $58.71 on Aug 16. The insider now owns 0 shares following the transaction. On Aug 16, Chief Medical Officer Garren Hideki sold 2,000 shares at $58.74 apiece. The transaction was valued at $117,480.
Valuation Metrics
The stock’s beta is 0.41. Besides these, the trailing price-to-sales (P/S) ratio of 52.98, the price-to-book (PB) ratio of 5.18.
Financial Health
In the three months ended June 29, Prothena Corporation plc’s quick ratio stood at 9.50, while its current ratio was 9.50, showing that the company is able to pay off its debt. Based on annual data, PRTA earned $185.46 million in gross profit and brought in $53.91 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -19.80%. Return on equity (ROE) for the past 12 months was -25.40%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. PRTA’s revenue rose 67.41% to $2.17 million during the quarter, while net income inched up to $4.02 million. While analysts expected Prothena Corporation plc to report -$1 quarterly earnings, the actual figure was -$1.03 per share, beating the consensus estimate by -3.00%. During the quarter, the company generated -$64.7 million in EBITDA. The liabilities of Prothena Corporation plc were 138.97 million at the end of its most recent quarter ended June 29, and its total debt was $3.45 million. The value of shareholders’ equity is $53.53 million.
Technical Picture
This quick technical analysis looks at Prothena Corporation plc’s (PRTA) price momentum. With a historical volatility rate of 19.86%, the RSI 9-day stood at 23.64% on 18 August.
With respect to its five-day moving average, the current Prothena Corporation plc price is down by -8.63% percent or -$5.36. At present, PRTA shares trade -12.71% below its 20-day simple moving average and +18.62% percent above its 100-day simple moving average. However, the stock is currently trading approximately -21.50% below its SMA50 and -7.63% below its SMA200.
Stochastic coefficient K was 10.78% and Stochastic coefficient D was 12.20%, while ATR was 2.68. Given the Stochastic reading of 7.36% for the 14-day period, the RSI (14) reading has been calculated as 30.28%. As of today, the MACD Oscillator reading stands at -2.29, while the 14-day reading stands at -4.16.
Analyst Ratings
SVB Securities launched its rating on Prothena Corporation plc (NASDAQ: PRTA) to an Outperform in a note to investors on April 24, 2023. Prothena Corporation plc (PRTA) has been rated Buy by analysts. According to 0 brokerage firms, PRTA is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Prothena Corporation plc stock as buy, with 8 recommending it as overweight.
With a median target price of $90.00, the current consensus forecast for the stock is $60.00 – $129.00. Based on these forecasts, analysts predict Prothena Corporation plc (PRTA) will achieve an average price target of $93.44.
